Roche Reports Phase III METEOROID Study Results for MOGAD

Why It Matters

The data could establish the first approved disease‑modifying treatment for MOGAD, reshaping standards of care and opening a sizable niche market for Roche’s neurology portfolio.

Key Takeaways

• Enspryng cut relapse risk by 68% in Phase III METEOROID.
• 87% of patients remained relapse‑free at 48 weeks versus 67% placebo.
• Annualised relapse rate fell 66%; MRI lesions down 79%.
• Rescue therapy use dropped 73%; hospitalisations fell 17%.
• Safety profile matches NMOSD data, no new concerns identified.

Pulse Analysis

MOGAD, a rare autoimmune disorder targeting the optic nerves, brain and spinal cord, has long lacked a disease‑modifying therapy. Patients typically rely on high‑dose steroids, plasma exchange, or intravenous immunoglobulin to manage acute attacks, but these interventions do not prevent future relapses and carry significant side‑effects. The unmet clinical need has spurred interest in biologics that can modulate the underlying immune response, a space where Roche’s satralizumab—already approved for aquaporin‑4‑positive neuromyelitis optica—offers a promising mechanistic fit.

The METEOROID trial enrolled adults and adolescents aged 12 and older, randomising them to subcutaneous Enspryng or placebo for 48 weeks. The study’s primary endpoint—time to first relapse—was met with a 68% risk reduction, while 87% of treated participants stayed relapse‑free compared with 67% on placebo. Secondary outcomes reinforced the benefit: annualised relapse rates fell 66%, MRI‑active lesions dropped 79%, and the need for rescue therapies decreased by 73%. Importantly, the safety signal mirrored prior NMOSD experience, with common adverse events limited to mild injection‑site reactions and flu‑like symptoms, and no new safety concerns emerging.

Roche’s announcement arrives as the company also reported success with fenebrutinib in relapsing multiple sclerosis, underscoring a broader strategic push into neuro‑immunology. If regulatory approval follows, Enspryng could become the first marketed therapy specifically for MOGAD, granting Roche a first‑to‑market advantage and potentially unlocking reimbursement pathways for a disease affecting a few thousand patients in the United States. The data also provide a template for future trials targeting other rare neuro‑inflammatory conditions, reinforcing Roche’s reputation for translating targeted biologics into clinical practice.